62978-73-8

Basic information

• Product Name: 5-ACETYL-8-HYDROXY-1H-QUINOLIN-2-ONE
• Synonyms: 5-ACETYL-8-HYDROXY-1H-QUINOLIN-2-ONE;5-ACETYL-QUINOLINE-2,8-DIOL;5-Acetyl-8-hydroxy-2(1H)-quinolinone;5-Acetyl-1,2-dihydro-8-hydroxy-2-oxoquinoline, 1-(1,2-Dihydro-8-hydroxy-2-oxoquinolin-5-yl)ethan-1-one;5-Acetyl-8-hydroxyquinolin-2(1H)-one;5-acetyl-8-hydroxy-1,2-dihydroquinolin-2-one;2(1H)-Quinolinone, 5-acetyl-8-hydroxy-;5-Acetyl-8-hydroxycarbostyril
• CAS NO: 62978-73-8
• Molecular Formula: C₁₁H₉NO₃
• Molecular Weight: 203.19
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 62978-73-8.mol
• Article Data: 17

Chemical Properties

• Melting Point: >260℃
• Boiling Point: 509.485 °C at 760 mmHg
• Flash Point: 261.927 °C
• Appearance: /
• Density: 1.336
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.62
• CAS DataBase Reference: 5-ACETYL-8-HYDROXY-1H-QUINOLIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ACETYL-8-HYDROXY-1H-QUINOLIN-2-ONE(62978-73-8)
• EPA Substance Registry System: 5-ACETYL-8-HYDROXY-1H-QUINOLIN-2-ONE(62978-73-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Hazardous Substances Data: 62978-73-8(Hazardous Substances Data)

Usage

Uses

5-Acetylquinoline-2,8-diol can be used in the preparation of 5-Acetylcarbostyril oxime derivatives as β2 adrenoreceptor agonists.

InChI:InChI=1/C11H9NO3/c1-6(13)7-2-4-9(14)11-8(7)3-5-10(15)12-11/h2-5,14H,1H3,(H,12,15)

Upstream product

• 75-36-5 acetyl chloride 
• 15450-76-7 8-Hydroxy-1H-quinolin-2-one 
• 148-24-3 8-quinolinol 
• 1127-45-3 8-Hydroxyquinoline-N-oxide 
• 108-24-7 acetic anhydride 
• 15450-72-3 2-oxo-1,2-dihydroquinolin-8-yl acetate 
• 22614-69-3 8-methoxy-1H-quinolin-2-one 
• 62978-76-1 acetyl-5 methoxy-8 carbostyrile 

Downstream Products

• 956235-09-9 5-acetyl-8-[(4-methoxyphenyl)methoxy]-1,2-dihydroquinolin-2-one 
• 93609-84-8 5-acetyl-8-benzyloxy-1H-quinolin-2-one 
• 1254102-83-4 5-(2-bromoacetyl)-8-[(4-methoxyphenyl)methoxy]-1,2-dihydroquinolin-2-one 
• 1254102-84-5 5-[(1R)-2-bromo-1-hydroxyethyl]-8-[(4-methoxyphenyl)methoxy]-1,2-dihydroquinolin-2-one 
• 1254098-87-7 4-[({5-[2-({[4-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)phenyl]methyl}carbamoyl)ethyl]-2-phenylphenyl}carbamoyl)oxy]-1,1-dimethylpiperidin-1-ium trifluoroacetate 
• 100331-89-3 8-benzyloxy-5-(2-bromoacetyl)-1H-quinolin-2-one 
• 530084-79-8 8-(benzyloxy)-5-[(1R)-2-bromo-1-hydroxyethyl]quinolin-2(1H)-one 
• 1254102-12-9 (R)-5-(2-azido-1-hydroxyethyl)-8-(benzyloxy)quinolin-2(1H)-one 
• 112281-28-4 8-benzyloxy-5-(epoxyethyl)-(1H)-quinolin-2-one 
• 956235-29-3 tert-butyl benzyl[2-({6-[(2-hydroxy-2-{8-[(4-methoxybenzyl)oxy]-2-oxo-1,2-dihydroquinolin-5-yl}ethyl)amino]hexyl}oxy)ethyl]carbamate 
• 956235-10-2 {8-[(4-methoxybenzyl)oxy]-2-oxo-1,2-dihydroquinolin-5-yl}(oxo)acetaldehyde 
• 753498-25-8 indacaterol maleate 
• 312753-06-3 indacaterol 
• 435273-75-9 (R)-8-(benzyloxy)-5-[2-[(5,6-diethyl-2,3-dihydro-1H-indole-2-yl)amino]-1-hydroxyethyl]quinolin-2(1H)-one 

Relevant articles and documents

Novel Quinolone Derivatives: Synthesis and Antioxidant Activity

Abstract: Novel quinolone derivatives have been designed and readily synthesized according to a simple protocol including O-alkylation and Claisen rearrangement processes. Structures of the synthesized compounds have been confirmed by IR, 1H and 13C NMR, and mass spectra. The new products have been tested for their antioxidant activity, and two of those demonstrate high antioxidant activity.

CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE

The invention provides a class of compounds represented by formula (I), having bifunctional active quaternary ammonium salt structure of a β2-adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, and optical isomer thereof. A pharmaceutical composition comprising such a compound with quaternary ammonium salt structure, a method for preparing such a compound with quaternary ammonium salt structure and an intermediate thereof, and uses thereof in treating pulmonary disorders are also provided. The compounds of the invention have high selectivity to the M receptor subtype, and have less adverse reaction and lower toxic and side effects in the treatment of pulmonary diseases such as COPD and asthma.

Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity

This invention provides compounds of formula I: wherein R1, R2, R4, R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.